Effect of Probiotics Supplementation on Heart Rate: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Shufen Han1,2*, Yuezhen Li2, Ruijuan Song2, Hui Gao3 and Weiguo Zhang4*

1 School of Public Health, Hangzhou Normal University, Hangzhou, China, 2 Department of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China, 3 Prefecture Center for Disease Control and Prevention, Jiaxing, China, 4 Independent Researcher, Irving, TX, United States

Background and Aims: Probiotics consumption lowers the risk of cardiovascular disease, but whether it affects heart rate (HR) remains controversial. Therefore, our study aimed to assess the chronotropic effects of probiotics on heartbeat via a meta-analysis of randomized clinical trials.

Methods: Relevant studies were identified by searching PubMed, Cochrane library, and Clinical Trials databases up to October 2021. Either a fixed-effects or a random-effects model was used to calculate the pooled effect sizes and 95% confidence intervals (CIs).

Results: This meta-analysis included 13 studies involving 16 interventional trial arms and 931 participants according to inclusion criteria. The overall pooled estimate showed that probiotics supplementation had a slight, but no significant reduction of 0.28 bpm (95% CI: −1.17, 0.60) on HR. Relatively high heterogeneity was observed among included trials (I² = 80.8%, P heterogeneity < 0.001). Subgroup analysis displayed that probiotics supplementation significantly reduced HR by 2.94 bpm (95% CI: −5.06, −0.82) among participants with baseline HR ≥ 75 bpm, by 1.17 bpm (95% CI: −2.34, −0.00) with probiotics dose ≥ 1 × 10¹⁰ CFU/day, and by 1.43 bpm (95% CI: −2.69, −0.17) with multiple-strain intervention. Meta-regression analysis showed that baseline HR was a major potential effect modifier of probiotics supplementation on lowering HR.

Conclusion: Hitherto, the overall evidence in the literature was insufficient to support the notion that probiotics supplementation has a class effect on HR reduction. However, in subgroup analysis, probiotics reduced HR significantly in those who had higher baseline HR, received a higher dose or multiple strains of probiotics.

Keywords: probiotics, heart rate, cardiovascular risk factor/disease, randomized controlled trials, meta-analysis
INTRODUCTION

Heart rate (HR) is determined by cardiac automaticity and highly regulated by the autonomic nervous system that consists of both parasympathetic and sympathetic nerves. Given its role in predicting cardiovascular disease in patients with cardiovascular disease and in the general population, elevated resting HR has been now considered a cardiovascular risk factor (1–3). For example, in a 4-year follow-up of 43,725 participants without metabolic syndrome at baseline, the odds ratio of developing metabolic syndrome was 1.41 over 4 years in those with resting HR of 95–104 bpm compared with 55–64 bpm after adjustment for confounding factors (4). More importantly, mounting evidence has demonstrated that resting HR is a potent predictor of cardiovascular mortality (1, 2). An increase in home-measured resting HR by 5 bpm was associated with a 17% increase in 10-year cardiovascular mortality (5). A recent meta-analysis including 87 prospective studies reported that a greater resting HR with each 10 bpm increment was associated with a 15% higher risk for cardiovascular disease and 18% for heart failure (6). As such, HR has emerged as a potential target for better health outcomes (7, 8).

As suggested by the Food and Agriculture Organization and World Health Organization in 2002, probiotics are live microorganisms that confer a health benefit on the host when consumed in adequate amounts (9). With growing interest in the gut microbiome, probiotics have received considerable attention for human health and wellbeing. A few review articles have shown that the administration of probiotics has certain potentials in producing protective and therapeutic benefits against heart failure and cardiovascular disease by targeting some cardiovascular disease risk factors, such as obesity, hypertension, and dyslipidemia (10–12). The possible mechanisms by which probiotics present their roles are related to the restoration of microbiota diversity, and the reduction of pro-inflammatory molecules and various metabolites. Given the importance of HR in health and disease, it is well-justified to ask whether probiotics supplementation, has a chronotropic effect on the heartbeat in humans. To date, the effect of probiotics supplementation on resting HR has been explored in a fair number of populations and health conditions.

METHODS

Literature Search Strategy

A systematic literature search for English publications was performed for RCTs to evaluate the effect of probiotics supplementation on HR in the databases of PubMed, Web of Science, and Cochrane library up to October 2021. The following search terms were applied: including “probiotics or probiotic drinks or probiotic pills or probiotic tablets or probiotic capsules or probiotic sachet or probiotic agent or probiotic products or probiotic supplementation or probiotic fortification” combined with “heart rate OR HR OR pulse rate OR PR OR heartbeat”. For additional studies, the bibliographies of retrieved papers and published systematic reviews were also carefully retrieved. We did not attempt to contact the corresponding authors for further information and did not try to take the unpublished articles into consideration. Each search result was independently reviewed for eligibility by two authors, with disagreement resolved by discussion. The present meta-analysis was planned, conducted, and reported in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA) (26).

Study Selection

After reviewing the titles and abstracts, full-text manuscripts were screened according to the following inclusion criteria: (1) studies were conducted with human participants with more than 18 years; (2) randomized clinical trial evaluating the effects of probiotics on HR; (3) probiotics was the only active components of the treatment effect; (4) had an intervention duration of not <2 weeks; (5) had a placebo-controlled group; (6) reported the net changes of HR, and their corresponding standard deviations (SDs), or available data to calculate their values. When probiotics were administered for multiple time durations in a study, the results from the longest time were used in the present meta-analysis. The intervention groups taking probiotic-fortified yogurts or probiotic-fortified beverages were included in the present study.

Data Extraction and Quality Assessment

Two authors (S.H. and Y.L.) extracted the following information from the selected studies via using a standardized data-collection sheet: the first author’s name, publication year, country, study design details, sample size, intervention duration, participant characteristics (mean age, sex, and health status), type and dose of probiotics, methods of HR assessment, baseline and final HR, a net change of HR and their corresponding SD. The quality of eligible studies was assessed according to the risk of bias criteria detailed in the Cochrane Handbook for Systematic Reviews of Interventions (The Cochrane Collaboration, 2017). The Jadad scale was used to evaluate the methodological quality of each included trial by assigning scores ranging from 1 to 7 (where <3 indicates low-quality study, 3–4 moderate quality, >4 high-quality) based on a study’s randomization, blinding, withdrawals and dropouts (27).

Data Synthesis and Statistical Analysis

In the present meta-analysis, probiotics were considered as the intervention arm. The net changes in HR were calculated as the difference between final and baseline values in the intervention and control groups, respectively. Studies with no reported SD had their values imputed from standard errors, confidence interval (CI), or P-values using a standard formula for the analysis (28). The homogeneity of the effect size among studies was tested using the Cochran Q test at a significance level of P < 0.10 level of significance. We also calculated the I² statistic, a quantitative measure of inconsistency across studies (29). An I² value > 50% was deemed to indicate substantial heterogeneity across
trials. In the presence of significant heterogeneity, the random-effects model was used to assess the overall effect size, otherwise, the fixed-effects model was acceptable. A pre-specified subgroup analysis was conducted to determine the possible effects of study designs and participant characteristics on the overall effect size. A sensitivity analysis was performed to investigate the influence of a single study on the overall effect estimate by omitting one study at each turn while pooling the results from the remainder. Furthermore, we performed a meta-regression analysis to explain possible sources of heterogeneity across studies. Potential publication bias was assessed through the Begg funnel plots and the Egger regression test (30). All analyses were performed using STATA version 11.0 (StataCorp, College Station, TX). $P < 0.05$ was considered statistically significant, except where otherwise specified.

RESULTS

Literature Selection and Trial Characteristics

After the literature search, a total of 188 records were found in our initial literature selection, and 13 eligible studies were incorporated based on study design and inclusion criteria in this meta-analysis (13–25). Among 13 studies, two studies had more than one targeting population (19, 25) and one study had two probiotic species administered separately (23), thereby consisting
of 16 intervention arms. A flow chart showing the selection process is presented in Figure 1.

The characteristics of the selected studies including 13 RCTs and their 16 intervention arms are shown in Table 1. The trials were published from 2005 to 2020 by various investigators. The sample size varied from 19 to 120, with a total of 931 participants. In terms of the study design, all the trials had a parallel design and participants received treatment in capsules, tablet, sachet, or a specially fortified yogurt or milk or drink with or without probiotics; one trial was triple-blind, three trials did not report the blindness, and the remaining were double-blind. The duration of probiotics administration ranged from 2 to 16 weeks with a median of 6 weeks. Ten trials used a single strain to intervene, and the remaining used multiple strains. The dose of most probiotics ranged from $3.0 \times 10^5$ to $22.5 \times 10^{10}$, and species of probiotics were presented in Table 1. Two studies did not mention the dosage of probiotics (22, 25). Two studies registered pulse rate (15, 25), and the remaining reported HR. One study observed the combined effect of probiotics and 20 mg of iron compared to 20 mg of iron alone (18). For the study from Patterson, we selected HR of sitting post-Trier Social Stress Test for 20 min as the final HR (14). For the Jadad scale, 5 individual trials scored 5, 5 trials scored 4, 4 trials scored 3, and 2 trials scored 2.

With regard to participants, ten trials enrolled men and women, whereas four included only men and two only women. The mean age of participants ranged from 19.0 to 68.0 years old. The participants of nine trials were healthy, in other trials suffered from overweight ($n = 2$), hypertension ($n = 2$), hypercholesterolemia ($n = 1$), iron-deficiency ($n = 1$), and laryngeal cancer ($n = 1$). The baseline HR of participants in almost all trials was within the normal range from 68.8 to 90.0 bpm. Most of the studies reported no significant side effects of probiotics supplementation.

**Effect of Probiotics on HR**

The net changes in HR between the probiotics supplementation and control groups ranged from $-2.20$ to 11.4 bpm. Considering a great heterogeneity ($P < 0.01, I^2 = 82.7\%$), the random-effect model was applied in the present meta-analysis. The pooled effect of probiotics supplementation on HR was $-0.28$ bpm (95% CI: $-1.17$ to 0.60; Figure 2), compared with the control group. This result indicated that probiotics supplementation had no effect on HR.

**Subgroup and Sensitivity Analysis**

The results of subgroup analysis were shown in Table 2. Overall, probiotics supplementation produced a significant HR reduction among these trials at male participants ($-2.70$ bpm; 95% CI: $-4.35$ to $-1.05$), the mean age $\geq 45$ years old ($-1.57$ bpm; 95% CI: $-3.07$ to $-0.06$), a probiotics dose $\geq 1 \times 10^{10}$ CFU/day ($-1.17$ bpm; 95% CI: $-2.34$ to $-0.00$), and with a baseline HR $\geq 75$ bpm ($-2.94$ bpm; 95% CI: $-5.06$ to $-0.82$) and a multiple-strain intervention ($-1.43$ bpm; 95% CI: $-2.69$ to $-0.17$). Inversely, probiotics produced a slight HR elevation at female participants ($2.59$ bpm; 95% CI: 0.83–4.34) and a probiotics dose $<1 \times 10^{10}$ CFU/day (2.03 bpm; 95% CI, 0.45–3.60). A sensitivity analysis was performed by omitting one trial each in turn to yield a narrow range from $-0.73$ (95% CI, $-1.70$ to 0.24) to $-0.01$ (95% CI, $-0.90$ to 0.88). The result suggested that no particular study significantly affected the overall findings for HR.

**Meta-Regression Analysis**

In order to explain the sources of heterogeneity, a meta-regression analysis was performed. To minimize the likelihood of false-positive results, we carefully selected a small number of covariates, including mean age, daily probiotics dose, and baseline HR. The present meta-analysis suggested that baseline HR was significantly associated with the effect estimate ($P = 0.002$) and accounted for 60.42% of the total between-study variation. By contrast, mean age and daily probiotics were not associated with a net change in HR ($P = 0.486, 0.819$). Therefore, baseline HR was considered as a major source of heterogeneity among trials.

**Publication Bias**

Begg's test suggested no evidence of publication bias for the outcomes ($P = 0.964$). Egger's test also did not indicate evidence of publication bias ($P = 0.586$).

**DISCUSSION**

Probiotics are most frequently consumed in the forms of dietary supplements or beverages (31). The present meta-analysis comprehensively reviewed 13 RCTs with 16 intervention trial arms that evaluated the effect of probiotics administration as supplementation on HR in adults with or without diseases. To the best of our knowledge, this is the first meta-analysis exploring the relationship between probiotics supplementation and HR. The pooled effects based on the meta-analysis suggested that probiotics supplementation were insufficient to change HR. However, a higher probiotics dosage with more than $1 \times 10^{10}$ CFU/day decreased HR by 1.17 bpm; a multiple-strain probiotics combination decreased HR by 1.43 bpm. We speculated that the negative chronotropic effect of probiotics on HR is dose-dependent and is enhanced when more strains are combined. In addition, the HR reduction by probiotics supplementation is profound in males or participants with the mean age $\geq 45$ years old or baseline HR $\geq 75$ bpm.

The present meta-analysis followed the PRISMA guidelines and had a relatively high Jadad score. However, it was limited primarily by considerable heterogeneity among studies, which complicated the interpretation of our findings. This phenomenon is perceivable because of the variation of the study characteristics. In trials included in the present meta-analysis, investigated strains were different; some administered single strain, others administered multiple strains. It is natural that each species and its metabolites interact with the host differently. Also, the participants included healthy adults, as well as patients with hypertension, hypercholesterolemia, iron deficiency, or laryngeal cancer. Health status may also differently affect the pharmacodynamics of probiotics on HR. In addition, genetic background or gene-diet interaction may partly explain the source of heterogeneity among studies. Due to the limited
| References (Country) | Study design | Sample size* | Male (%) | Age (year) | Duration | Probiotic compound | Heart rate measurement | Baseline HR (bpm)* | Participant characteristics | Jadad scores |
|----------------------|--------------|--------------|----------|------------|----------|-------------------|------------------------|-------------------|--------------------------|-------------|
| Adikari et al. (13) (Malaysia) | P, DB | 10/9 | 100 | 19.0 | 8 weeks | Lactobacillus Casei Shirata strain with 3 × 10^{10} CFU/d | NeuLog™ Heart Rate sensor | 76.0 ± 16.1 | Football players | 5 |
| Patterson et al. (14) (Finland) | P, DB | 55/57 | 50 | 23.4 | 5 weeks | Lactocaseibacillus paracasei Lpc-37® with 1.75 × 10^{10} CFU/d | A Polar watch device, Polar Electro GmbH | 72.3 ± 13.7 | Healthy adults | 5 |
| Karbownik et al. (15) (Poland) | P, DB | 31/29 | 38 | 22.7 | 30 days | Saccharomyces Boullardii CNCM I-1079 with 5 × 10^{9} CFU/d | Self-recorded by palpation at the radial artery | 68.8 ± 9.5 | Healthy medical students | 3 |
| Romão da Silva et al. (16) (Brazil) | P, TB | 19/17 | 0 | 43.5 | 8 weeks | Probiotop® at a dosage of 4 × 10^{9} CFU/d | Electrocardiogram | 70.0 ± 2.8 | Hypertensive women | 4 |
| Pacifici et al. (17) (Italy) | P, DB | 20/20 | 100 | 33.5 | 10 weeks | Hypobiotics PRO-15 ADVANCED STRENGTH with 225 billion CFUs | No report | 73.2 ± 7.0 | Oral surgeons | 5 |
| Axling et al. (18) (Sweden) | P, DB | 19/23 | 0 | 21.9 | 12 weeks | Lactobacillus plantarum 299v (Lp299v) with 1 × 10^{10} CFU/d | Polar heart rate monitor with a Polar H7 Sensor | – | Female iron-deficient athletes | 3 |
| Ibrahim et al. (19) (Malaysia) | P, NR | 10/10 | 100 | 22.5 | 12 weeks | Hexbio® granule with 3 × 10^{10} CFU/d | OMRON | 72.2 ± 3.5 | Sedentary young males | 2 |
| | P, NR | 9/12 | 100 | 21.4 | 12 weeks | Hexbio® granule with 3 × 10^{10} CFU/d | OMRON | 72.4 ± 3.1 | Circuit training for young males | 2 |
| Lefevre et al. (20) (France) | P, DB | 50/50 | 21 | 63.2 | 16 weeks | 2 × 10^{6} spores of B. subtilis CFU/d | No report | 74.6 ± 12.2 | Healthy free-living elderly subjects | 4 |

(Continued)
| References (Country) | Study design | Sample size* | Male (%) | Age (year) | Duration | Probiotic compound | Heart rate measurement | Baseline HR (bpm)* | Participant characteristics | Jadad scores |
|---------------------|--------------|--------------|----------|------------|----------|---------------------|------------------------|----------------------|--------------------------|-------------|
| Möller et al. (21) (Pennsylvania) | P, DB | 57/48 | 34 | 20.2 | 2 weeks | 3\textsuperscript{a}VSL#3 with 112.5 billion CFUs a day | Critikon Dinamap Oscillometric Stationary Monitor | 79.1 ± 11.5<br>78.9 ± 13.0 | Young adults | 3 |
| Yang et al. (22) (China) | P, B | 10/10 | 50 | 58.1 | 2 weeks | Clostridium butyricum, 420 mg/capsule, twice daily | No report | 89.0 ± 8.5<br>90.0 ± 9.0 | Laryngeal cancer patients | 3 |
| Ivey et al. (23) (Australia) | P, DB | 40/37 | 57 | 68.0 | 6 weeks | Probiotic yogurt with Lactis Bb12 dose of 3.0 × 10\textsuperscript{9} CFU/d | Automated home blood pressure monitor | 71.0 ± 9<br>71.0 ± 9 | Overweight | 5 |
| P, DB | 39/40 | 58 | 65.0 | 6 weeks | Control milk with Lactis Bb12 dose of 3.0 × 10\textsuperscript{9} CFU/d | Automated home blood pressure monitor | 70.0 ± 14.0<br>72.0 ± 12.0 | Overweight | 5 |
| Jones et al. (24) (Canada) | P, DB | 59/61 | 36 | 50.4 | 6 weeks | Microencapsulated L. reuteri NCIMB 30242 in a yogurt formulation with 5 × 10\textsuperscript{10} CFU, twice daily | No report | 75.9 ± 4.8<br>75.4 ± 6.2 | Mild hypercholesterolemic adults | 4 |
| Aihara et al. (25) (Japan) | P, DB | 20/20 | 65 | 51.4 | 4 weeks | Powdered fermented milk with L. helveticus CM4, 12 g/day | UDEX-SUPER automatic sphygmomanometer | 71.9 ± 6.7<br>71.2 ± 8.0 | High-normal blood pressure | 4 |
| P, DB | 20/20 | 80 | 51.7 | 4 weeks | Powdered fermented milk with L. helveticus CM4, 12 g/day | UDEX-SUPER automatic sphygmomanometer | 73.4 ± 6.3<br>73.4 ± 7.3 | Mild hypertension | 4 |

\textsuperscript{a}For parallel design, sample size and heart rate are intervention group/control group.
\textsuperscript{b}Probiotop\textsuperscript{®} contains Lactobacillus paracasei LPC-37, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM, and Bifidobacterium lactis HN019 at a dosage of 10\textsuperscript{9} CFU of each strain.
\textsuperscript{c}Hyperbiotics PRO-15 ADVANCED STRENGTH contains 15 different probiotics patented strains (Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium infantis, Lactobacillus fermentum, Lactobacillus casei, Bifidobacterium longum, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus salivarius, Lactobacillus paracasei, Bifidobacterium bifidum, Lactobacillus gasseri, Bifidobacterium breve, and Streptococcus thermophilus).
\textsuperscript{d}Hexbio\textsuperscript{®} granule contains six different microorganism strains (L. acidophilus BCMC\textsuperscript{®} 12130, L. casei BCMC\textsuperscript{®} 12313, L. lactis BCMC\textsuperscript{®} 12451, B. bifidum BCMC\textsuperscript{®} 02290, B. infantis BCMC\textsuperscript{®} 02129, and B. longum BCMC\textsuperscript{®} 02120).
\textsuperscript{e}VSL\#3, freeze-dried probiotic bacteria, contains Bifidobacterium breve, B. longum, B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, L. bulgaricus, and Streptococcus thermophilus.

P, parallel; B, blind; DB, double blind; TB, triple blind; NR, no reporting blind; CFU, colony-forming unit.
number of trials and the sample size, this meta-analysis did not further explore the effect based on these characteristics. The observed heterogeneity might be attributed to the two trials because the heterogeneity disappeared after the two trials were excluded in the sensitivity analysis. In the trial by Kabornik et al., the participants went through a stress test through a final academic exam, and HR was increased by probiotics supplementation (15). This increase may be partly attributable to the influence of a stress test before supplementation, because the stress may increase HR as an indirect marker of mental and physical stress (32). In the trial by Yang et al., the participants were a special population with laryngeal cancer and their baseline HR is the highest among all trials. In this trial, HR is surprisingly decreased by 22 bpm (22).

The results of subgroup analysis suggested the different influences of probiotics dose and strain on HR. HR reduction was more pronounced when probiotics supplementation with more than $1 \times 10^{10}$ CFU/day or multiple probiotics strains, suggesting that probiotics dose and strain were two important factors influencing HR. In the definition of probiotics, it is required the administration of an adequate amount in order to obtain a health benefit. A systematic review also reported that probiotics with a larger dose daily exhibited a significant reducing effect on blood pressure and other diseases (33, 34). However, meta-regression analysis showed that probiotics dose was not a major source of heterogeneity among trials, so further trials with different doses are required to confirm these findings considering the small sample of trials in each subgroup. Furthermore, trials using multiple probiotics strains showed a statistically significant reduction in HR, while trials with a single strain had no effect on HR. The possible mechanism is attributed to the synergistic or additive effect of several probiotics; therefore, further studies are warranted to validate this finding.

Subgroup analysis results also indicated a significant reduction of HR in males or participants with the mean age $\geq 45$ years old or baseline HR $\geq 75$ bpm. Based on the meta-regression analysis, the baseline HR of subjects was a primary source of heterogeneity among trials, while the mean age was not. Although the baseline HR from the included trials was within the normal reference value, HR has been proved as an important marker of outcome in cardiovascular disease (35). From a Systolic Hypertension in Europe study, resting HR $> 79$ bpm was a significant predictor of all-cause and cardiovascular mortality in elderly patients with systolic hypertension (36). In our meta-analysis, HR with 75 bpm was acted as a cut-off point for subgroup analysis. A decrease in HR is helpful to reduce the risk of cardiovascular mortality. Thus,
TABLE 2 | Subgroup analyses according to trial and participant characteristics.

| Subgroup                        | No | Net bpm change (95% CI) | P-heterogeneity | I² (%) |
|---------------------------------|----|-------------------------|-----------------|--------|
| **Sex**                         |    |                         |                 |        |
| Male                            | 4  | −2.70 (−4.35, −1.05)    | 0.276           | 22.4   |
| Female                          | 2  | 2.59 (0.83, 4.34)       | 0.384           | 0      |
| Male and female                 | 10 | −0.36 (−1.67, 0.95)     | 0.000           | 83.6   |
| **Mean age, year**              |    |                         |                 |        |
| <45                             | 9  | 0.40 (−0.70, 1.50)      | 0.000           | 82.1   |
| ≥45                             | 7  | −1.57 (−3.07, −0.06)    | 0.000           | 79.2   |
| **Study duration**              |    |                         |                 |        |
| <6 weeks                        | 6  | 0.61 (−1.31, 2.52)      | 0.000           | 90.4   |
| ≥6 weeks                        | 10 | −0.53 (−1.67, 0.95)     | 0.003           | 63.7   |
| **Health status**               |    |                         |                 |        |
| Generally healthy               | 11 | −0.71 (−1.90, 0.47)     | 0.000           | 72.5   |
| Disease status                  | 5  | 0.26 (−1.07, 1.60)      | 0.000           | 90.1   |
| **Baseline HR, bpm**            |    |                         |                 |        |
| <75 bpm                         | 12 | 0.28 (−0.69, 1.26)      | 0.000           | 76.3   |
| ≥75 bpm                         | 4  | −2.94 (−5.06, −0.82)    | 0.000           | 87.6   |
| **Form of probiotics**          |    |                         |                 |        |
| Capsule or sachet               | 10 | 0.10 (−1.15, 0.96)      | 0.000           | 88.0   |
| Milk or yogurt or juice         | 6  | −0.72 (−2.35, 0.91)     | 0.748           | 0      |
| **Probiotics dose**             |    |                         |                 |        |
| <10^{10} CFU                    | 5  | 2.03 (0.45, 3.60)       | 0.001           | 79.6   |
| ≥10^{10} CFU                    | 8  | −1.17 (−2.34, −0.00)    | 0.012           | 61.3   |
| **Number of strains of probiotics** | | | | |
| Single-strain                   | 10 | 0.83 (−0.41, 2.08)      | 0.000           | 70.4   |
| Multiple-strain                 | 6  | −1.43 (−2.69, −0.17)    | 0.000           | 87.9   |

the present finding is useful, because probiotics supplementation might be effective in subjects with a high HR level.

Sub-diaphragmatic sensory nerves project centrally via the vagal afferents and dorsal spinal roots to reflexively regulate sympathetic or parasympathetic efferent nerve activities or tune their balance (37, 38). The favorable alteration of the gut microbial ecosystem is the most characterized biological function of probiotics (39, 40). Other than impacting the local environment, it regulates the excitability of the afferent nerves. The gastrointestinal afferents are an indispensable component of the microbiota-gut-brain axis in perceiving the information from the gut microbial ecosystem and then conveying it to the central nervous system (41, 42), which is another controlling mechanism on HR besides cardiac automaticity. From a dietary and nutrition perspective, the coupling between the gut-brain axis and the cardiac system is a new and interesting research field. Indeed, animal studies demonstrated that the change of gut microbial ecosystem either by prebiotics to proliferate probiotics population or by direct probiotics administration could prevent cardiovascular dysfunction by improving gut microbiota diversity and maintaining vascular integrity (43–45). In order to promote cardiovascular health and disease prevention to a wider population, further studies may identify and verify unique probiotics that may have better efficacy, safety, and feasibility profiles, and elucidate their mechanism of action in reducing HR.

In this meta-analysis, there are a few noteworthy limitations. First, relatively high heterogeneity was observed in all included trials. Therefore, the findings from this meta-analysis should be interpreted with caution. Considering the amount of the trials reporting no effect on HR, the observed heterogeneity across trials should be caused by the difference in statistical significance between trials rather than the difference in direction of the effect size. Second, the health status of participants varied widely across trials, and this might lead to overestimation or underestimation of the true intervention effect. However, the predefined subgroup and sensitivity analyses showed that the health status of participants did not affect the overall effect size. Third, the validity of our meta-analysis is dependent on the quality of the individual studies, but well-designed studies were not many. Specifically, allocation concealment, quality of randomization, and details of withdrawals were not always reported. Fourth, subgroup analysis showed that a higher probiotics dose can decrease HR. While this makes common sense, without having a dose-response curve established, it cannot be generalized now. Finally, the probiotics strain types investigated were diverse, which, on one hand, allows for cross-analysis of the relationship between more strains and the heart
rate responses, on the other hand, disallowed for an accurate assessment of the efficacy of an individual strain.

CONCLUSION
In conclusion, the evidence collected from published literature as of October 2021 was insufficient to prove the hypothesis that there is a class effect of probiotics supplementation on HR reduction in the overall analysis. Interestingly, however, probiotics reduced HR significantly in males, and in those who were relatively older (≥45 years) or with higher baseline HR (≥75 bpm), received a higher dose (≥10^4 CFU/day), or multi-strain of probiotics in subgroup analysis. Meta-regression analysis demonstrated that baseline HR was a potential effect modifier and a major contributor to the overall between-study variation, therefore, the present results should be interpreted with caution because of the existence of heterogeneity. Taken together, it is justified to pursue future investigations on a larger scale, with an adequate dosage of promising strain(s), and with a targeted population(s) for the purpose of HR reduction, which will determine if some probiotics constitute an effective, safe, and applicable dietary or nutrition approach in the strategic framework of lifestyle modification for cardiovascular risk control and disease prevention.

REFERENCES
1. Zhang GQ, Zhang W. Heart rate, lifespan, and mortality risk. Ageing Res Rev. (2009) 8:52–60. doi: 10.1016/j.arr.2008.10.001
2. Perret-Guillaume C, Joly J, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. (2009) 52:6–10. doi: 10.1016/j.pcad.2009.05.003
3. Palatini P. Resting heart rate as a cardiovascular risk factor in hypertensive patients: an update. Am J Hypertens. (2021) 34:367–17. doi: 10.1093/ajh/hpaa187
4. Jiang X, Liu X, Wu S, Zhang GQ, Peng M, Wu Y, et al. Metabolic syndrome is associated with and predicted by resting heart rate: a cross-sectional and longitudinal study. Heart. (2015) 101:44–9. doi: 10.1136/heartjnl-2014-305685
5. Hozawa A, Ohkubo T, Kikuya M, Ugaij T, Yamaguchi J, Asayama K, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. (2004) 17:1005–10. doi: 10.1016/S0895-7061(04)00897-0
6. Aune D, Sen A, o’Hartaigh B, Janszky I, Romundstad PR, Tonstad S, et al. Prognostic value of home heart rate for cardiovascular mortality in hypertensive patients: an update. Am J Hypertens. (2021) 34:367–17. doi: 10.1093/ajh/hpaa187
7. Zhang GQ, Zhang W. Heart rate, lifespan, and mortality risk. Ageing Res Rev. (2009) 8:52–60. doi: 10.1016/j.arr.2008.10.001
8. Perret-Guillaume C, Joly J, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. (2009) 52:6–10. doi: 10.1016/j.pcad.2009.05.003
9. Palatini P. Resting heart rate as a cardiovascular risk factor in hypertensive patients: an update. Am J Hypertens. (2021) 34:367–17. doi: 10.1093/ajh/hpaa187
10. Sun J, Buys N. Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Ann Med. (2015) 47:430–40. doi: 10.3109/07853890.2015.1071872
11. Ettinger G, MacDonald K, Reid G, Burton JP. The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes. (2014) 5:719–28. doi: 10.4161/19490976.2014.983775
12. Dixon A, Robertson K, Yung A, Que M, Randall H, Wellaladogade D, et al. Efficacy of probiotics in patients of cardiovascular disease risk: a systematic review and meta-analysis. Curr Hypertens Rep. (2020) 22:74. doi: 10.1007/s11906-020-01080-y
13. Adikari A, Appukuttu M, Kuan G. Effects of daily probiotics supplementation on anxiety induced physiological parameters among competitive football players. Nutrients. (2020) 12:1920. doi: 10.3390/nu12051920
14. Patterson E, Griffin SM, Ibarra A, Ellisiepen E, Hellhammer J. Lactociaeaeibacillus paracasei Lpc-37(R) improves psychological and physiological markers of stress and anxiety in healthy adults: a randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study). Neurobiol Stress. (2020) 13:100277. doi: 10.1016/j.ynstr.2020.10.002
15. Karbownik MS, Kreczynska J, Kwarta P, Cybula M, Wiktorowska-Owczarek A, Kowalczyk E, et al. Effect of supplementation with saccharomyces boulardi on academic examination performance and related stress in healthy medical students: a randomized, double-blind, placebo-controlled trial. Nutrients. (2020) 12:1469. doi: 10.3390/nu12051469
16. Romão da Silva LF, de Oliveira Y, de Souza EL, de Luna Freire MO, Braga VA, Magnani M, et al. Effects of probiotic therapy on cardiovascular and metabolic parameters and autonomic modulation in hypertensive women: a randomized, triple-blind, placebo-controlled trial. Food Funct. (2020) 11:7152–63. doi: 10.1039/D0FO01661F
17. Pacifi A, Pacifi C, Nuzzolesi M, Castell M, Ballini A, Santacroce L, et al. The alteration of stress-related physiological parameters after probiotics administration in oral surgeries with different degrees of surgical experience. Clin Ter. (2020) 171:197–208. doi: 10.7417/CT.2020.2214
18. Axling U, Önnin G, Combs MA, Bogale A, Högström M, Svensson M. The effect of lactobacillus plantarum 299v on iron status and physical performance

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS
SH and WZ: study design and analysis and interpretation of data. SH, YL, and HG: literature search. SH, YL, and RS: data collection, extraction, and quality assessment. SH: writing-original draft. WZ: writing-review and editing. All the authors reviewed and approved the final manuscript.

FUNDING
This study was supported by Scientific Research Foundation for Scholars of HZNU (No.2022QDL004).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.829703/full#supplementary-material
in female iron-deficient athletes: a randomized controlled trial. *Nutrients*. (2020) 12:1279. doi: 10.3390/nu12051279
19. Ibrahim NS, Muhamad AS, Ooi FK, Meor-Osman J, Chen CK. The effects of combined probiotic ingestion and circuit training on muscular strength and power and cytokine responses in young males. *Appl Physiol Nutr Metab.* (2018) 43:180–6. doi: 10.1139/apnm-2017-0464
20. Lefevere M, Racedo SM, Denayrolles M, Ripert G, Desfougères T, Lobach AR, et al. Safety assessment of *Bacillus subtilis* CUI for use as a probiotic in humans. *Regul Toxicol Pharmacol.* (2017) 83:54–65. doi: 10.1016/j.yrtph.2016.11.010
21. Möller CM, Olsa EJA, Ginty AT, Rapelje AL, Tindall CL, Holesh LA, et al. Influence of acute multispecies and multistrain probiotic supplementation on cardiovascular function and reactivity to psychological stress in young adults: a double-blind, randomized, placebo-controlled trial. *Psychosom Med.* (2017) 79:914–9. doi: 10.1097/PSY.0000000000001489
22. Yang H, Zhao X, Tang S, Huang H, Zhao X, Ning Z, et al. Probiotics reduce psychological stress in patients before laryngeal cancer surgery. *Asia Pac J Clin Oncol.* (2016) 12:e92–6. doi: 10.1111/ajco.12120
23. Ivey KL, Hodgson JM, Kerr DA, Thompson PL, Stojceski B, Prince RL. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. *Nutr Metab Cardiovasc Dis.* (2015) 25:46–51. doi: 10.1016/j.numecd.2014.07.012
24. Jones ML, Martoni CJ, Tamber S, Parent M, Prakash S. Evaluation of safety and tolerance of microencapsulated *Lactobacillus reuteri* NCIMB 30242 in a yoghurt formulation: a randomized, placebo-controlled, double-blind study. *Food Chem Toxicol.* (2012) 50:2216–23. doi: 10.1016/j.fct.2012.03.010
25. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk with *Lactobacillus helveticus* on subjects with high-normal blood pressure or mild hypertension. *J Am Coll Nutr.* (2005) 24:257–65. doi: 10.1080/07317524.2005.10719473
26. Page MJ, McKenzie JE, Bossuyt PM, Bouter L, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71
27. Jadad AR, Enkin MW. *Randomized Controlled Trials: Questions, Answers and Methods*. 2nd ed. London: BMJ Books (2007).
28. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. The Cochrane Collaboration (2011). Available online at: https://handbook-5-1.cochrane.org
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629
31. McFarland LV. From yakis to yoghurt: the history, development, and current use of probiotics. *Clin Infect Dis.* (2015) 60(suppl_2):S85–90. doi: 10.1093/cid/civ054
32. Thayer JF, Ahs F, Fredrikson M, Sollers JJ III, Wager TD. A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health. *Neurosci Biobehav Rev.* (2012) 36:747–56. doi: 10.1016/j.neubiorev.2011.11.009
33. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. *Hypertension*. (2014) 64:897–903. doi: 10.1161/HYPERTENSIONAHA.114.03469
34. Ouwehand AC. A review of dose-responses of probiotics in human studies. *Benef Microbes.* (2017) 8:143–51. doi: 10.3920/BM2016.0140
35. Bohm M, Reil JC, Deedwania P, Kim JB, Borger JS. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. *Am J Med*. (2015) 128:219–28. doi: 10.1016/j.amjmed.2014.09.016
36. Palatini P, Thijis L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. *Arch Intern Med.* (2002) 162:2313–21. doi: 10.1001/archinte.162.20.2313
37. Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. *Am J Hypertens.* (2000) 13:999–1004. doi: 10.1016/S0895-7061(00)00288-0
38. Zhang W, Li J, Hosaka M, Jian R, Shelton JM, Albright GM, et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. *Proc Natl Acad Sci USA.* (2000) 97:9765–70. doi: 10.1073/pnas.170160397
39. Sanchez B, Delgado S, Blanco-Miguez A, Lourenco A, Guimondes M, Margolles A, Probiotics, gut microbiota, and their influence on host health and disease. *Mol Nutr Food Res.* (2017) 61:1600240. doi: 10.1002/mnfr.201600240
40. Obrenovich M, Siddiqui B, McCloskey B, Reddy VP. The microbiota-gut-brain axis heart shunt part I: The French paradox, heart disease and the microbiota. *Microorganisms*. (2020) 8:4990. doi: 10.3390/microorganisms8040490
41. Breit S, Kuperberg A, Rogler G, Hasler G. Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. *Front Psychiatry.* (2018) 9:44. doi: 10.3389/fpsyg.2018.00404
42. Morkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the microbiota-gut-brain axis: focus on psychiatry. *Curr Nutr Rep.* (2020) 9:171–82. doi: 10.1007/s13668-020-00313-5
43. Gao H, Song R, Li Y, Zhang W, Wan Z, Wang Y, et al. Effects of oat fiber intervention on cognitive behavior in LDLR−/− mice modeling atherosclerosis by targeting the microbiome-gut-brain axis. *J Agric Food Chem.* (2020) 68:14480–91. doi: 10.1021/acs.jafc.0c05677
44. Guiuramas KSL, Braga VA, Noronha S, Costa W, Makki K, Cruz JC, et al. *Lactiplantibacillus plantarum* WJL administration during pregnancy and lactation improves lipid profile, insulin sensitivity and gut microbiota diversity in dyslipidemic dams and protects male offspring against cardiovascular dysfunction in later life. *Food Funct.* (2020) 11:8939–50. doi: 10.1039/D0FO01718C
45. Kong CY, Li ZM, Mao YQ, Chen HL, Hu W, Han B, et al. Probiotic yogurt blunts the increase of blood pressure in spontaneously hypertensive rats via remodeling of the gut microbiota. *Food Funct.* (2021) 12:9773–83. doi: 10.1039/D1FO01836A

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Han, Li, Song, Gao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.